Atrium Therapeutics, Inc Common Stock
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $3,004 | $19,635 | $859 | $12,475 |
Gross Profit | 2,661 | 19,484 | 859 | 12,475 |
EBITDA | -22,275 | -16,482 | -47,913 | -8,394 |
EBIT | -22,618 | -16,633 | -48,035 | -8,463 |
Net Income | -20,186 | -16,633 | -48,069 | -8,287 |
Net Change In Cash | 3,004 | 19,635 | 859 | 12,475 |
Free Cash Flow | -3,962 | -33,241 | -20,131 | -160,060 |
Cash | 72,645 | 267,849 | 270,000 | 270,000 |
Basic Shares | 17,106 | 17,105 | 17,114 | 137,895 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $18,618 | $10,897 | $9,560 | $9,224 |
Gross Profit | 18,618 | 10,897 | 7,459 | 9,224 |
EBITDA | -76,503 | -376,160 | -233,497 | -177,526 |
EBIT | -76,826 | -378,936 | -235,598 | -178,913 |
Net Income | -76,684 | -322,302 | -212,220 | -169,077 |
Net Change In Cash | 18,618 | 10,897 | 9,560 | 9,224 |
Free Cash Flow | -42,574 | -307,936 | -123,292 | -139,091 |
Cash | 270,000 | 219,868 | 185,082 | 340,396 |
Basic Shares | 17,114 | 111,582 | 73,012 | 52,162 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$1.18 |
2026-03-31 | -$0.97 |
2025-12-31 | -$1.59 |
2025-09-30 | -$1.27 |